A revolutionary method for targeted neurotherapeutics is focused ultrasound (FUS)-mediated blood-brain barrier (BBB) regulation. In order to enable controlled and targeted intracerebral drug delivery, recent developments in hybrid extracellular vessssicle-nanoparticle (EV-NP) platforms combine the biological compatibility of natural vesicles with the adjustable characteristics of synthetic nanocarriers. The engineering approaches, translational difficulties, and molecular underpinnings of FUS-activated EV-NP hybrids are all thoroughly examined in this paper. Mechanistically, FUS uses acoustic cavitation to provide a temporary and reversible opening of the blood-brain barrier, which allows therapeutic medicines to pass through selectively while reducing side effects. Thermosensitive lipid and perfluorocarbon inclusion, ligand-mediated targeting, and stimuli-responsive surface design are examples of engineering advancements that improve biodistribution and release accuracy. When compared to traditional systems, preclinical models show higher therapeutic indices, prolonged drug retention, and brain penetration efficiencies of up to 90%. Large-scale production, standardization, and regulatory validation still face difficulties, nevertheless, especially with regard to long-term safety and reproducibility. New developments have a strong emphasis on combining synthetic biology, microfluidics, and artificial intelligence to improve design parameters and guarantee clinical scalability. All things considered, FUS-activated EV-NP hybrids offer a potential new avenue for precision neuropharmacology, bridging the gap between next-generation tailored therapies and non-invasive delivery methods.
Keywords: Focused ultrasound (FUS); blood-brain barrier (BBB); engineering strategies.; extracellular vesicle (EV); hybrid drug delivery; nanoparticles (NPs); neurotherapeutics.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.